top of page

Checking in with Artiva CEO Fred Aslan after the NK cell focused company's $167 million IPO

He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page